There have been many studies that are being conducted in order to measure the DAPA-HF trial. This has been even faced in around dapagliflozin diagnosed patients. There have been many observations that have been granted so far in order to measure heart failure hospitalization. Therefore, for the purpose of conducting this study, the patients in the New York Heart Association was conducted using the functional class II and IV. an attempt was made to ensure the insertion of a left ventricular ejection. The results concluded that around 37 percent of the patients were known for having reacted positively to the abovementioned clause. In addition, 28.8 percent in the group known for reading the components in a nice manner. The median follows up was around the period of 18.4 months. The adjusted risk of death from any cause after an outpatient worsening was the hazard ratio which was around the percentile of 95 percent. The DAPA-HF outpatient episodes of HF were worsening were extremely common and hence, were of extremely prognostic importance. This was even followed by the reduced injection of dapagliflozin.
Ref art: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047480
